ONL Therapeutics (ONL) is a biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal diseases and conditions, including retinal detachment and both the wet and dry forms of age-related macular degeneration (AMD).
By advancing a novel breakthrough technology designed to block programmed cell death (apoptosis), ONL is pioneering an entirely new approach to preserving sight. It is the first and only company focused on preventing the death of key retinal cells, including photoreceptors – the root cause of vision loss, the leading cause of blindness and a completely unaddressed medical need.
ONL is pioneering an entirely new approach to preserving sight.
Based on its industry-leading expertise in vision protection, ONL is developing breakthrough, first-in-class treatments for serious, vision-threatening retinal diseases and conditions. Preclinical in vivo data, along with a growing body of literature, support potential application of the company’s technology platform in retinal detachment, age-related macular degeneration (AMD) and other chronic retinal diseases.
ONL’s lead therapeutic candidate, ONL1204, is a first-in-class small molecule peptide initially being developed for the protection of key retinal cells, including photoreceptors, in retinal detachment. The company is currently working to complete preclinical development activities for ONL1204 with the intention of submitting an investigational new drug (IND) application and initiating our Phase I/II clinical trials in retinal detachment in the first half of 2016. Concurrent with our retinal detachment efforts, ONL will complete preclinical activities for chronic indications such as AMD.
Combined, the estimated market for the initial indications that ONL plans to target is >$12 billion globally. ONL believes that retinal detachment alone represents a >$500M global market opportunity.
ONL has been granted orphan drug designation in retinal detachment, providing the company with seven years of post-approval exclusivity in that indication. Additionally, the company possesses a strong and wide-ranging intellectual property portfolio around both the Fas pathway and composition of its drug candidates, as well as strong management and expert advisory teams with decades of experience in drug development and retinal disease.
Initial indications represent a >$12B worldwide market opportunity.